Skip to main content
Livermore
Livermore
ZHEN

First Trust Advisors LP

SEC CIK
0001125816
Latest filing
Aug 11, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by First Trust Advisors LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
1,417,063
Value
$110.9M
% of portfolio
0.1%
Quarters held
22
Since Q1 2021
Holdings of HALO by First Trust Advisors LP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,417,063$110.9M0.1%−65,277−4.4%ReducedHolders
Q1 20261,482,340$95.8M0.1%+470,558+46.5%AddedHolders
Q4 20251,011,782$68.1M<0.1%+235,371+30.3%AddedHolders
Q3 2025776,411$56.9M<0.1%+10,493+1.4%AddedHolders
Q2 2025765,918$39.8M<0.1%−37,776−4.7%ReducedHolders
Q1 2025803,694$51.3M<0.1%−55,878−6.5%ReducedHolders
Q4 2024859,572$41.1M<0.1%−17,291−2.0%ReducedHolders
Q3 2024876,863$50.2M<0.1%−149,303−14.5%ReducedHolders
Q2 20241,026,166$53.7M0.1%−168,298−14.1%ReducedHolders
Q1 20241,194,464$48.6M<0.1%+1,102,623+1,200.6%AddedHolders
Q4 202391,841$3.39M<0.1%+84,288+1,116.0%AddedHolders
Q3 20237,553$288.5K<0.1%+1,941+34.6%AddedHolders
Q2 20235,612$202.4K<0.1%−99,668−94.7%ReducedHolders
Q1 2023105,280$4.02M<0.1%+51,110+94.4%AddedHolders
Q4 202254,170$3.08M<0.1%−56,923−51.2%ReducedHolders
Q3 2022111,093$4.39M<0.1%+30,639+38.1%AddedHolders
Q2 202280,454$3.54M<0.1%+28,865+56.0%AddedHolders
Q1 202251,589$2.06M<0.1%−5,138−9.1%ReducedHolders
Q4 202156,727$2.28M<0.1%−65,434−53.6%ReducedHolders
Q3 2021122,161$4.97M<0.1%+37,835+44.9%AddedHolders
Q2 202184,326$3.83M<0.1%−54,754−39.4%ReducedHolders
Q1 2021139,080$5.80M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.